NCT03185052

Brief Summary

Over the past years, arterial closure systems have tended to replace manual compression to ensure hemostasis at femoral artery puncture points. Arterial closure systems reduce hemostasis and patient immobilization times, thus enabling early resumption of walking. These devices have contributed extensively to the development of outpatient stays for cardiology, vascular and neuro-radiology procedures. According to certain studies however, it would appear that arterial closure devices do not present any greater benefits than manual compression in terms of hemostasis and complications. Moreover, the use of increasingly small diameter instruments would tend to render manual compression sufficient. Finally, the use of these devices generates additional costs. The purpose of our prospective study is to evaluate the feasibility and safety of same-day discharge after manual compression in patients treated for peripheral artery disease by endovascular technique with 5F sheath.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
116

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2017

Typical duration for not_applicable

Geographic Reach
1 country

10 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 7, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 14, 2017

Completed
4 months until next milestone

Study Start

First participant enrolled

September 27, 2017

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 10, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 10, 2019

Completed
Last Updated

November 21, 2019

Status Verified

November 1, 2019

Enrollment Period

2 years

First QC Date

June 7, 2017

Last Update Submit

November 20, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Total in-hospital admission rate

    Total in-hospital admission rate includes unplanned overnight surveillance and re-hospitalization rate at 1 month.

    1 month

Secondary Outcomes (14)

  • Death (all causes) at 1 month.

    1 month

  • Unplanned overnight surveillance rate

    1 month

  • Re-hospitalization after discharge during M1

    1 month

  • Occurrence of major events during the perioperative period (H0 to M1)

    1 month

  • Occurrence of major punctured femoral artery events during the perioperative period (H0 to M1)

    1 month

  • +9 more secondary outcomes

Study Arms (1)

Manual puncture point compression

OTHER

Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter

Other: Manual puncture point compression

Interventions

Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter

Manual puncture point compression

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \> 18 years,
  • Endovascular treatment by stent or drug coating balloon 5F and 0.035 compatible
  • Femoral approach
  • Outpatient hospitalization
  • Manual compression at puncture site
  • Rutherford 2 to 5
  • Patient affiliated with a social security scheme
  • Patient's signed informed consent form

You may not qualify if:

  • Under-age patient
  • Patient of age, but under legal guardianship or care
  • Contraindication to endovascular treatment
  • Use of a 6F or greater sheath
  • Radial or brachial puncture
  • Acute ischemia
  • Anticoagulant treatment or hemostasis disorder
  • Allergy to Elastoplast® type adhesive strips
  • Life expectancy of less than one month
  • Refusal of patient to participate in the study
  • Participation in another therapeutic trial
  • Pregnant woman, lactating women
  • Patients do not understand the French language or unfit for proposed follow in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

CHU de Besançon

Besançon, France

Location

CHU de Bordeaux

Bordeaux, France

Location

AP-HP, Hôpital Ambroise Paré

Boulogne-Billancourt, France

Location

CHU de Clermont Ferrand

Clermont-Ferrand, France

Location

CHU de DIJON

Dijon, France

Location

Clinique de Fontaine-Les- Dijon

Dijon, France

Location

Nantes University Hospital

Nantes, France

Location

AP-HP, Hôpital Européen Georges Pompidou

Paris, France

Location

Institut Mutualiste Montsouris

Paris, France

Location

Clinique de l'Europe

Rouen, France

Location

MeSH Terms

Conditions

Peripheral Arterial Disease

Condition Hierarchy (Ancestors)

AtherosclerosisArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesPeripheral Vascular Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 7, 2017

First Posted

June 14, 2017

Study Start

September 27, 2017

Primary Completion

October 10, 2019

Study Completion

October 10, 2019

Last Updated

November 21, 2019

Record last verified: 2019-11

Data Sharing

IPD Sharing
Will not share

Locations